Clinical Trial Update: Genetic-Dependent Cardiovascular Response to PPAR-Alpha Agonist Fenofibrate [NA]

View source ↗

Summary

A completed clinical trial investigated how genetic differences influence cardiovascular responses to the PPAR-Alpha agonist fenofibrate in individuals with Typ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• FENOFIBRATE (Fenofibrate)

Snippet

Sponsor: Mario Luca Morieri | Conditions: Type 2 Diabetes, Cardiovascular Diseases | NA | Status: COMPLETED